Wall Street brokerages expect that BioTime, Inc. (NASDAQ:BTX) will report earnings of ($0.06) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for BioTime’s earnings. The lowest EPS estimate is ($0.09) and the highest is ($0.03). BioTime also posted earnings of ($0.06) per share during the same quarter last year. The company is expected to report its next earnings report on Thursday, August 1st.

On average, analysts expect that BioTime will report full-year earnings of $0.07 per share for the current fiscal year, with EPS estimates ranging from ($0.01) to $0.14. For the next financial year, analysts anticipate that the company will report earnings of ($0.28) per share, with EPS estimates ranging from ($0.43) to ($0.17). Zacks’ EPS averages are an average based on a survey of research firms that that provide coverage for BioTime.

BioTime (NASDAQ:BTX) last announced its quarterly earnings results on Thursday, May 9th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.36. The company had revenue of $0.93 million for the quarter, compared to analysts’ expectations of $0.66 million.

BTX stock traded up $0.07 during trading on Monday, hitting $1.24. 618,539 shares of the company traded hands, compared to its average volume of 735,406. The stock’s 50-day moving average is $1.09. BioTime has a 1 year low of $0.66 and a 1 year high of $2.81.

About BioTime

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Featured Article: Coverage Ratio

Get a free copy of the Zacks research report on BioTime (BTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.